gemfibrozil has been researched along with Atypical Mycobacterial Infection, Disseminated in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, YS | 1 |
| Kim, JK | 1 |
| Hanh, BTB | 1 |
| Kim, SY | 1 |
| Kim, HJ | 1 |
| Kim, YJ | 1 |
| Jeon, SM | 1 |
| Park, CR | 1 |
| Oh, GT | 1 |
| Park, JW | 1 |
| Kim, JM | 1 |
| Jang, J | 1 |
| Jo, EK | 1 |
1 other study available for gemfibrozil and Atypical Mycobacterial Infection, Disseminated
| Article | Year |
|---|---|
The Peroxisome Proliferator-Activated Receptor α- Agonist Gemfibrozil Promotes Defense Against
Topics: Animals; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Mice; Mycobacterium Infections, Nontubercu | 2020 |